Effect of food on the bioavailability of prednisone. 1976

A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner

Two commercial prednisone tablets were studied which had previously been shown by Sullivan et al.5,6 to have the slowest and fastest in vitro rates of dissolution, and the slowest and fastest rise to peak plasma prednisolone concentrations in human beings. The effect of food on the adsorption of these two tablets was studied in a crossover study, which also repeated the fasting conditions used by Sullivan et al.6 Marked differences in mean prednisolone plasma concentrations during the 0- to 2-hour absorption phase were observed between the two tablets again, but food did not affect either tablet with respect to mean plasma prednisolone concentrations.

UI MeSH Term Description Entries
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
January 1987, The American journal of gastroenterology,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
January 1980, Annual review of pharmacology and toxicology,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
January 1986, European journal of clinical pharmacology,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
November 1989, Zeitschrift fur Stomatologie (1984),
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
April 2001, Biopharmaceutics & drug disposition,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
April 1980, British journal of clinical pharmacology,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
March 2017, Cancer chemotherapy and pharmacology,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
January 1978, Acta medica Scandinavica,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
October 1994, Journal of clinical pharmacology,
A V Tembo, and E Sakmar, and M R Hallmark, and D J Weidler, and J G Wagner
January 1982, European journal of clinical pharmacology,
Copied contents to your clipboard!